Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. pharmaceutical companies with strong positions in various therapeutic areas. Lilly’s growth is bolstered by its GLP-1 drugs, Mounjaro and Zepbound, which are projected to generate significant revenue, while AbbVie has successfully transitioned from the loss of exclusivity of Humira to new immunology drugs, Skyrizi and Rinvoq. Both companies show robust financial performance, with Lilly forecasting higher revenue and EPS growth for 2026, driven by innovative therapies and a strong pipeline. AbbVie, despite facing some near-term challenges, also expects continued growth supported by acquisitions and its diversified product range. While AbbVie offers more attractive valuation metrics and a higher dividend yield, Lilly is favored for growth potential, making it a better choice for growth-oriented investors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/zacks:844fa2b6f094b:0-lly-or-abbv-which-drugmaker-is-likely-to-offer-better-upside-in-2026/
